Acerus Pharmaceuticals (OTCMKTS:TRLPF) will announce its earnings results before the market opens on Tuesday, November 6th.
Acerus Pharmaceuticals (OTCMKTS:TRLPF) last announced its quarterly earnings data on Friday, August 10th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $2.10 million during the quarter. Acerus Pharmaceuticals had a negative net margin of 198.08% and a negative return on equity of 192.40%.
Shares of OTCMKTS TRLPF opened at $0.17 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.73 and a current ratio of 1.01. Acerus Pharmaceuticals has a 12-month low of $0.09 and a 12-month high of $0.40.
About Acerus Pharmaceuticals
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.
Recommended Story: Discount Rate
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.